JP2022512781A5 - - Google Patents

Info

Publication number
JP2022512781A5
JP2022512781A5 JP2021521816A JP2021521816A JP2022512781A5 JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5 JP 2021521816 A JP2021521816 A JP 2021521816A JP 2021521816 A JP2021521816 A JP 2021521816A JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5
Authority
JP
Japan
Application number
JP2021521816A
Other languages
Japanese (ja)
Other versions
JP2022512781A (ja
JPWO2020092655A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058973 external-priority patent/WO2020092655A1/en
Publication of JP2022512781A publication Critical patent/JP2022512781A/ja
Publication of JP2022512781A5 publication Critical patent/JP2022512781A5/ja
Publication of JPWO2020092655A5 publication Critical patent/JPWO2020092655A5/ja
Priority to JP2024213792A priority Critical patent/JP2025038016A/ja
Pending legal-status Critical Current

Links

JP2021521816A 2018-10-30 2019-10-30 同種造血幹細胞移植の方法 Pending JP2022512781A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213792A JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752828P 2018-10-30 2018-10-30
US62/752,828 2018-10-30
US201862773873P 2018-11-30 2018-11-30
US62/773,873 2018-11-30
US201962882362P 2019-08-02 2019-08-02
US62/882,362 2019-08-02
PCT/US2019/058973 WO2020092655A1 (en) 2018-10-30 2019-10-30 Methods for allogeneic hematopoietic stem cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213792A Division JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Publications (3)

Publication Number Publication Date
JP2022512781A JP2022512781A (ja) 2022-02-07
JP2022512781A5 true JP2022512781A5 (https=) 2022-11-07
JPWO2020092655A5 JPWO2020092655A5 (https=) 2022-11-07

Family

ID=70462151

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521816A Pending JP2022512781A (ja) 2018-10-30 2019-10-30 同種造血幹細胞移植の方法
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Country Status (12)

Country Link
US (1) US20210379195A1 (https=)
EP (1) EP3877415A4 (https=)
JP (2) JP2022512781A (https=)
KR (1) KR20210086683A (https=)
CN (1) CN113301923A (https=)
AU (1) AU2019374055A1 (https=)
BR (1) BR112021008437A2 (https=)
CA (1) CA3117366A1 (https=)
IL (1) IL282637A (https=)
MX (1) MX2021004579A (https=)
SG (1) SG11202104084WA (https=)
WO (1) WO2020092655A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740641A (zh) 2016-11-30 2020-01-31 杰克逊实验室 具有改善的人先天免疫细胞发育的人源化小鼠模型
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
GB202015226D0 (en) * 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
US12496303B2 (en) * 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
AU2022421979A1 (en) * 2021-12-22 2024-08-01 The Jackson Laboratory Humanized mouse models
WO2023118608A1 (en) * 2021-12-23 2023-06-29 Universität Basel Discernible cell surface protein variants of cd45 for use in cell therapy
EP4486784A1 (en) * 2022-03-01 2025-01-08 CSL Innovation Pty Ltd Methods of bone marrow conditioning

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558662B2 (en) * 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
NZ607906A (en) * 2010-08-18 2015-11-27 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3117367A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof
WO2020219959A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd45 antibody drug conjugates and uses thereof
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
EP4051711A4 (en) * 2019-11-01 2024-02-21 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES

Similar Documents

Publication Publication Date Title
BR112021018450A2 (https=)
BR112021017637A2 (https=)
JP2022512781A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112021017732A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)
BR112021018084A2 (https=)
BR112021017983A2 (https=)
BR112021018193A2 (https=)
BR112021017847A2 (https=)
BR112021016099A2 (https=)
CN304981164S (https=)
CN304979956S (https=)
CN304975981S (https=)